Replies to post #447347 on Anavex Life Sciences Corp (AVXL)

[kund]

Clown is talking about AD partnership since 2015, no one will partner or buy this POS, what value this company brings? all failed trials with post-hoc end points

[BIOChecker4]

The only thing behind Missling’s mention of Karuna was to titillate hopeful shareholders (something which he has had a lot of practice doing). It appears to have worked once again, at least for a few people.

The bottom line is today’s presentation was a disappointing nothing burger. It’s as if 2023 never happened.

DOG bless,

[Steady_T]

Seems to me that Missling was describing how the market values drugs with some similarities to 2-73. Not an immediate value but rather an ultimate value.

It will take an approval for an indication to realize that valuation. Once there is an approval that buyout indicates what 2-73 may be worth. Probably setting a floor value since 2-73 has a real possibility of additional indications.
IMHO